Breast Cancer Predictive Tests
Drug Discovery and Development
The Value of Prediction
Bioarray’s predictive tests are designed to transform cancer treatment decisions, improve patient quality of life and survival outcomes, and reduce healthcare costs. One of the leading issues in healthcare today is avoiding over treatment and determining the optimal treatment plan for cancer patients of all stages. Identifying more relevant treatment options upfront with clinically actionable information means avoiding harmful side effects from ineffective treatment and ultimately giving rise to more rational and effective treatments.
Bioarray’s has a growing pipeline of products:
BA100 Predictive Test of Pathologic Complete Response to Taxane-based Chemotherapy.
The Company’s lead test, BA100, predicts the likelihood that a breast cancer patient will achieve pathological complete response (pCR) as a result of the standard-of-care taxane/anthracycline neoadjuvant chemotherapy. Easy to interpret test results provided to patients and clinicians encompass quantitative probability scores and accurate personalized information used to plan the optimal course of treatment. The candidates for the BA100 predictive test are newly diagnosed invasive breast cancer patients with locally advanced, or early stage high risk disease (independent of lymph node status or subtype) that are eligible for neoadjuvant chemotherapy.
In addition to providing information regarding pCR, BA100 is able to identify the “difficult to treat” population of breast cancer patients who have the poorest rates of survival, including those with triple negative breast cancer. By stratifying subpopulations of patients with the worst survival rates, clinicians have the opportunity to modify the treatment plan at the front end of the journey to improve outcomes and reduce unnecessary toxicity. Presently there is unmet need to provide this valuable information to patients and clinicians.
BA100 is the first in a pipeline of predictive tests that leverage Bioarray’s intelligent platform. BA100 is currently recruiting for clinical utility studies.
GENE PROFILING PLATFORM
BA355 Gene Profiling Platform Accelerates Oncology Drug Discovery and Development
Bioarray’s BA355 gene profiling platform provides global insight into cancer treatment response to accelerate drug discovery and development. The RNA-biomarkers comprising the BA355 platform represent healthy organizational phenotypes in a physiologically relevant context. As a result, the selected biomarkers have greater utility in testing tumor samples. Specifically:
- 251 genes in the platform are novel and not present in nine other commercially available oncology gene panels
- 32 genes are currently drug treatment targets .
- The genes cover diverse interconnected cell signaling pathways relevant for oncology drug response.
The platform has been verified as a research & development tool in the most common cancer types including lung, colorectal, breast, prostate and ovarian cancer.
With the advent of new developments of drug combinations and targeted treatments, the ability to stratify patient populations for clinical trial accuracy has become increasingly important. Specifically, Bioarray’s platform can be used as a framework to stratify categories of patients, select patients for clinical trials, and develop companion diagnostics by providing a more in-depth and comprehensive view of gene expression profiles and key cellular signaling pathways.
The Company’s bioinformatics capabilities are platform agnostic, analyzing gene expression and genomic data from Affymetrix, Agilent, Illumina, and NanoString platforms.
The ability to analyze large amounts of complex data and generate novel information sets Bioarray apart from others. New information on pathways and their interconnections, the development of evidence-based biomarkers, and resulting actionable information set the foundation for optimization of drug discovery, and development of predictive tests and companion diagnostics.
Learn more about Bioarray and our high-value, proprietary product portfolio: firstname.lastname@example.org.